| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/22/2002 | CA2440743A1 Matrix gene expression in chondrogenesis |
| 08/22/2002 | CA2438658A1 Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent |
| 08/22/2002 | CA2438551A1 Ppar agonists |
| 08/22/2002 | CA2438501A1 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 08/22/2002 | CA2438492A1 Proliferative activator receptor (ppar) compounds |
| 08/22/2002 | CA2438153A1 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 08/22/2002 | CA2437890A1 Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| 08/22/2002 | CA2437823A1 Acrochordon alleviation |
| 08/22/2002 | CA2437811A1 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 08/22/2002 | CA2437731A1 A medicinal composition and use comprising turmeric extract for smoke detoxification |
| 08/22/2002 | CA2437643A1 Matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2437588A1 Triazolo compounds as mmp inhibitors |
| 08/22/2002 | CA2437576A1 Method for evaluating therapeutic efficacy |
| 08/22/2002 | CA2437402A1 New crystal forms of oxcarbazepine and processes for their preparation |
| 08/22/2002 | CA2437358A1 Agonists and antagonists of sphingosine-1-phosphate receptors |
| 08/22/2002 | CA2437333A1 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
| 08/22/2002 | CA2437122A1 Quinazolines as mmp-13 inhibitors |
| 08/22/2002 | CA2437118A1 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| 08/22/2002 | CA2436713A1 Proteins and nucleic acids encoding same |
| 08/22/2002 | CA2436371A1 Bicyclic pyrimidine matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2436079A1 Heterocyclic inhibitors of glycine transporter 2 |
| 08/22/2002 | CA2436068A1 Thrombin inhibitors |
| 08/22/2002 | CA2435376A1 Isophthalic acid derivatives as matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2434982A1 Pyridine matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2434641A1 Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| 08/22/2002 | CA2433843A1 Molecules for disease detection and treatment |
| 08/22/2002 | CA2433778A1 Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2433075A1 Benzo thiadiazine matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2431033A1 Crystallization of igf-1 |
| 08/22/2002 | CA2430726A1 Isolated human transporter proteins, nucleic acid molecules encoding them and uses thereof |
| 08/22/2002 | CA2426535A1 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors |
| 08/22/2002 | CA2401383A1 Compositions of biochemical compounds involved in bioenergy metabolism of cells and method of use |
| 08/21/2002 | EP1233021A2 An inhibitor of Beta amyloid cleavage enzyme |
| 08/21/2002 | EP1233018A2 Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors |
| 08/21/2002 | EP1233017A1 Tricyclic sulfonamides useful as matrix metalloproteinase inhibitors |
| 08/21/2002 | EP1233016A1 Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors |
| 08/21/2002 | EP1233013A1 Novel phenylalanine derivatives |
| 08/21/2002 | EP1232756A1 Drugs, drinks or foods |
| 08/21/2002 | EP1232284A1 Genomic polymorphism for predicting therapeutic response |
| 08/21/2002 | EP1232267A2 Activation of hcv-specific t cells |
| 08/21/2002 | EP1232264A2 Human fgf-21 gene and gene expression products |
| 08/21/2002 | EP1232263A2 Polypeptides and nucleic acids encoding same |
| 08/21/2002 | EP1232259A1 Human galanin family proteins and polynucleotides encoding the same |
| 08/21/2002 | EP1232247A2 Modulation of signal transduction |
| 08/21/2002 | EP1232180A1 Polypeptides derived from vitamin d nuclear receptor, and their uses in particular for screening vitamin d analogues |
| 08/21/2002 | EP1232174A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 08/21/2002 | EP1232170A1 Antimitotic compounds |
| 08/21/2002 | EP1232169A1 Gallotannins and ellagitannins as regulators of cytokine release |
| 08/21/2002 | EP1232159A1 Beta-amyloid peptide inhibitors |
| 08/21/2002 | EP1232155A1 Protease inhibitors |
| 08/21/2002 | EP1232154A1 Protease inhibitors |
| 08/21/2002 | EP1232153A2 Imidazole derivatives and their use as raf kinase inhibitors |
| 08/21/2002 | EP1232147A1 Triazoles as farnesyl transferase inhibitors |
| 08/21/2002 | EP1232144A2 Novel il-8 receptor antagonists |
| 08/21/2002 | EP1231983A2 Treatment of subnormal bone mineral density |
| 08/21/2002 | EP1231982A2 Use of phthalazine derivatives |
| 08/21/2002 | EP1231942A1 Cobalamin conjugates useful as imaging agents and as antitumor agents |
| 08/21/2002 | EP1231940A1 Stable amorphous amifostine composition, and preparation thereof |
| 08/21/2002 | EP1231939A2 Oncolytic combinations for the treatment of cancer |
| 08/21/2002 | EP1231938A2 Oncolytic combinations for the treatment of cancer |
| 08/21/2002 | EP1231934A2 Methods of inhibiting atrophy or promoting hypertrophy |
| 08/21/2002 | EP1231930A1 HUMAN IgM ANTIBODIES TO CHEMOKINE RECEPTORS |
| 08/21/2002 | EP1231923A1 Protease inhibitors |
| 08/21/2002 | EP1231922A1 Protease inhibitors |
| 08/21/2002 | EP1231921A1 Protease inhibitors |
| 08/21/2002 | EP1231920A1 Solutions containing epinastine |
| 08/21/2002 | EP1231919A2 Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| 08/21/2002 | EP1231918A2 Novel composition based on a thiazolidinedione and metformin and use |
| 08/21/2002 | EP1231916A2 Use of indirubine derivatives for making medicines |
| 08/21/2002 | EP1231914A2 Nordihydroguaiaretic derivatives for use in treatment of tumors |
| 08/21/2002 | EP1231913A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 08/21/2002 | EP1231907A2 Dextrose and insulin fluid formulation for intravenous infusion |
| 08/21/2002 | EP1231904A2 A method of microencapsulation |
| 08/21/2002 | EP1231895A1 Modular targeted liposomal delivery system |
| 08/21/2002 | EP1053224B1 Biphenylsulfonyl cyanamides, method for the production thereof and their utilization as a medicament |
| 08/21/2002 | EP1041991A4 Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha |
| 08/21/2002 | EP0983075B1 A method to increase the survival of transplanted cells |
| 08/21/2002 | EP0980251B1 Tissue factor for influencing blood vessel formation |
| 08/21/2002 | EP0956034B1 Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin |
| 08/21/2002 | EP0759757B1 Oral liquid alendronate formulations |
| 08/21/2002 | EP0756596B1 Tropane-2-aldoxime derivatives as neurotransmitter reuptake inhibitors |
| 08/21/2002 | EP0729358B1 Transdermal prostaglandin composition |
| 08/21/2002 | EP0675715B1 Cell differentiation induction with mevalonate and mevalonolactone derivatives |
| 08/21/2002 | EP0642580B1 Hepatocyte growth factor variants |
| 08/21/2002 | EP0637203B1 Regulation of the immune system |
| 08/21/2002 | CN1365392A Drosophila recombination-associated protein and methods for use |
| 08/21/2002 | CN1365361A Fused imiazole compounds and remedies for diabetes mellitus |
| 08/21/2002 | CN1365360A Puring derivatives inhibitors of tyrosine kinase SYK |
| 08/21/2002 | CN1365359A Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists |
| 08/21/2002 | CN1365356A Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect |
| 08/21/2002 | CN1365355A Quinoline derivatives as inhibitors of MEK enzymes |
| 08/21/2002 | CN1365354A Novel naphthylsulfonic acids and related compounds as glucose uptake agonists |
| 08/21/2002 | CN1365285A Neurotrophic factors in the treatment of peripheral nerve dysfunction of pelvia area |
| 08/21/2002 | CN1365281A Metalloprotease inhibitors |
| 08/21/2002 | CN1365280A 抗菌化合物 Antibacterial compounds |
| 08/21/2002 | CN1365277A Method for treating chronic pain using MEK inhibitors |
| 08/21/2002 | CN1364636A Medicament for curing short figure |
| 08/21/2002 | CN1364601A Nano Chaihuang heat clearing away medicine and its preparing method |
| 08/21/2002 | CN1364595A Nano Ruyi medicine and its preparing method |
| 08/21/2002 | CN1364594A Nano heat clearing away and acne eliminating medicine and its preparing method |